| References |
| Formulation |
10 µg affinity-purified IgG in 100 µl HEPES, pH 7.5, containing 50% glycerol, 0.01% BSA, and 0.15 M sodium chloride |
| Purity |
Affinity-purified |
| Stability |
1 year |
| Storage |
-20°C |
| Shipping |
Wet ice
in continental US; may vary elsewhere
|
| Specificity |
| Human p53 |
+ |
| Murine p53 |
+ |
| Rat p53 |
+ |
|
Background Reading
El-Deiry, W.S. The p53 pathway and cancer therapy. Cancer J 11 229-236 (1998).
Saito, S., Yamaguchi, H., Higashimoto, Y., et al. Phosphorylation site interdependence of human p53 post-translational modifications in response to stress. J Biol Chem 278(39) 37536-37544 (2003).
Lane, D.P., and Hupp, T.R. Drug discovery and p53. Drug Discov Today 8(8) 347-355 (2003).
| Size |
Global Purchasing |
| 1 ea |
|
Description
Antigen:
amino acids around phospho-Ser392
·
Host:
rabbit
·
Application(s):
WB; other applications not tested
·
This antibody was purified by sequential peptide-affinity chromatography to select only for IgG specific for p53 (Ser392). Cellular p53, often called the 'guardian of the genome', is a transcription factor that is activated in response to cellular stress (DNA damage, hypoxia, heat shock, etc.) and acts to prevent further proliferation of the stressed cell by induction of cell cycle arrest or apoptotic mediators.1 Nearly 50% of human tumors have mutated or non-functional p53. p53 amino acid residues can be modified by phosphorylation and acetylation. In vivo phosphorylation of p53 residues alters signal transduction that warrant further investigation.2,3
1
El-Deiry, W.S. The p53 pathway and cancer therapy. Cancer J 11 229-236 (1998).
2
Lane, D.P., and Hupp, T.R. Drug discovery and p53. Drug Discov Today 8(8) 347-355 (2003).
3
Saito, S., Yamaguchi, H., Higashimoto, Y., et al. Phosphorylation site interdependence of human p53 post-translational modifications in response to stress. J Biol Chem 278(39) 37536-37544 (2003).
|
